Structural and metabolic reprogramming by docosahexaenoic acid in neuronal cell models of Alzheimer’s disease
Biochimie · 2026-10
DOI: 10.1016/j.biochi.2026.10.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimie, 2026-10. Verfasst von Awdi Rana und 3 weiteren Autor:innen. Beteiligte Einrichtung: INSA Lyon, CNRS, LaMCoS, UMR5259, Villeurbanne, 69621, France; Université de Sherbrooke, Faculté de médecine et des sciences de la santé (FMSS), Sher…. Die Arbeit nennt 54 Literaturangaben. Gefördert von: Canadian Institutes of Health Research, Centre National de la Recherche Scientifique, Institut National des Sciences Appliquées de Lyon.
Themen: Demenz
Abstract (Originalsprache)
Docosahexaenoic acid (DHA; 22:6n-3) is the most abundant omega-3 polyunsaturated fatty acid in the mammalian brain and an essential structural component of neuronal membranes. Several research studies indicate that DHA plays critical roles in maintaining membrane lipid composition, synaptic integrity, mitochondrial function, and metabolic homeostasis, processes that are disrupted in Alzheimer's disease (AD) and other neurodegenerative disorders. Because brain DHA availability depends largely on systemic metabolism and liver-brain communication, alterations in DHA homeostasis have been proposed as contributing factors to AD pathogenesis. In vitro neuronal culture models have been pivotal in investigating the molecular and biochemical mechanisms underlying DHA-mediated neuroprotection under disease-related conditions. This mini review summarizes how DHA treatment modulates cellular membrane organisation, synaptogenesis and cytoskeletal integrity, and its neuroprotective role in in vitro neuronal models of AD. Collectively, the literature supports DHA as a key modulator of the structure and metabolic mechanisms at the cellular level and supports the hypothesis that its greatest benefit may occur as a preventive or early-stage intervention. Although effective therapeutic interventions are still lacking, and more investigations integrating next-generation cellular models are still needed, these models provide crucial insights for developing targeted therapeutic applications in AD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- INSA Lyon, CNRS, LaMCoS, UMR5259, Villeurbanne, 69621, France; Université de Sherbrooke, Faculté de médecine et des sciences de la santé (FMSS), Sherbrooke, QC, J1K 2R1, Canada; Centre de recherche sur le vieillissement…
- Université de Sherbrooke, Faculté de médecine et des sciences de la santé (FMSS), Sherbrooke, QC, J1K 2R1, Canada; Centre de recherche sur le vieillissement CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, J1H 4C4, Canada.
- INSA Lyon, CNRS, LaMCoS, UMR5259, Villeurbanne, 69621, France.
- INSA Lyon, CNRS, LaMCoS, UMR5259, Villeurbanne, 69621, France. Electronic address: nathalie.bernoud-hubac@insa-lyon.fr.
Förderung
- Canadian Institutes of Health Research
- Centre National de la Recherche Scientifique
- Institut National des Sciences Appliquées de Lyon
Zitieren
APA
Rana, A., Mélanie, P., Amanda, L. V., & Nathalie, B. H. (2026). Structural and metabolic reprogramming by docosahexaenoic acid in neuronal cell models of Alzheimer’s disease. Biochimie. https://doi.org/10.1016/j.biochi.2026.10.005
Vancouver
Rana A, Mélanie P, Amanda LV, Nathalie BH. Structural and metabolic reprogramming by docosahexaenoic acid in neuronal cell models of Alzheimer’s disease. Biochimie. 2026. doi:10.1016/j.biochi.2026.10.005
BibTeX
@article{Rana2026,
author = {Rana, Awdi and Mélanie, Plourde and Amanda, Lo Van and Nathalie, Bernoud-Hubac},
title = {Structural and metabolic reprogramming by docosahexaenoic acid in neuronal cell models of Alzheimer’s disease},
journal = {Biochimie},
year = {2026},
doi = {10.1016/j.biochi.2026.10.005}
}
EUVIMED